FDA authorizes, with special controls, direct-to-consumer test that reports three mutations in the BRCA breast cancer genes

Test only reports 3 out of more than 1,000 known BRCA mutations and negative result doesn't rule out increased cancer risk SILVER SPRING, Md., March 6, 2018 -- (Healthcare Sales & Marketing Network) -- The U.S. Food and Drug Administration today authori... Diagnostics, Oncology, FDA 23andMe, Genetic Health Risk, BRCA1, BRCA2, breast cancer
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news